Terns Pharmaceuticals halts its TERN-601 obesity program due to insufficient efficacy and safety concerns. Click here to read ...

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune ...

New hormonal and device-based methods could soon make male contraception reliable and reversible, offering alternatives to ...

212Pb-DOTAMTATE showed significant antitumor activity in PRRT-exposed GEP-NET patients, with a 34.6% ORR and 96.2% disease control rate per investigator review. Investigator-assessed 18-month PFS and ...

Analysts from William Blair and GlobalData critiqued the trial design for social anxiety disorder, though the latter notes ...

PSMA antigen implicated in disease biology withcontinued expression following androgen receptor pathway inhibitor (ARPI) ...

Researchers have engineered a rare type of immune cell to kill slow-growing bowel cancer cells that are resistant to current therapies.

October marks Menopause Awareness Month, a time to focus on the physical and emotional changes that affect more than 1 million American women each year. Fairhaven Health, a leader in women’s ...

Madrigal Pharmaceuticals sees rapid Rezdiffra sales growth with EU approval and long-term GLP-1 strategy. Learn why MDGL ...

New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETsFirst phase 2 study to evaluate TAT with ...

Researchers at the University of California, Irvine, have uncovered an unexpected molecular partnership that reshapes scientists' understanding of how brain inflammation arises in Alzheimer's disease.

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...